BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210624T190000
DTEND;TZID=Africa/Nairobi:20210624T203000
DTSTAMP:20260425T065351
CREATED:20210530T155634Z
LAST-MODIFIED:20231018T125500Z
UID:5217-1624561200-1624566600@kesho-kenya.org
SUMMARY:Role of New Therapies in the Management of ITP and Other Haematological Disorders
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Fatmah Abdallah\, Haematologist and pediatric Oncologist \nSponsor: Beacon \nPresenters: \n\nProf. Malkit Riyat\, Associate professor of hematology and Consultant hematologist\, Aga Khan University Hospital\, Nairobi\n\nImmune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disorder characterized by low platelet count. This may be as a result of platelet destruction or impaired platelet production. A platelet count in peripheral blood less than or equal to 100×10^9/L is the most important criterion for the diagnosis of ITP. It has an incidence of 2to 5 per 100\,000 persons and may be either primary or secondary. Pathogenetic mechanisms of ITP involve platelet autoantibodies\, T lymphocytes\, and impaired thrombopoiesis. Clinical presentation is the increased bleeding tendency\, petechiae\, and mucosal hemorrhages. Additional symptoms include exhaustion and fatigue\, depressive disorders\, anxiety\, increased risk of infection\, and iron deficiency anemia. Predictors of bleeding include severe thrombocytopenia\, chronic ITP\, history of major bleeding\, older age (>60 years)\, patients on anticoagulants or antiplatelet agents. The goal of treatment is to achieve adequate hemostasis and not to achieve a normal platelet count. Initiation of treatment should put into consideration the age of the patient\, upcoming surgery\, comorbidities associated with the risk of bleeding\, antiplatelet medications or anticoagulation\, distance from the hospital and ability to follow up\, and additional symptoms such as fatigue. Platelet count is the most important measure of disease activity and is inversely correlated with morbidity from bleeding.  Management of newly diagnosed ITP maybe by observation for individuals with a platelet count greater than or equal to 30×10^9/L and asymptomatic or minor mucocutaneous bleeding or by use of corticosteroids for individuals with a platelet count less than 30×10^9/L and asymptomatic or minor mucocutaneous bleeding. This is dependent on factors that impact the risk of bleeding\, including the degree of thrombocytopenia\, patient comorbidities\, medications\, and age. Other factors to consider include the disease duration\, access to care\, quality of life implications\, patient and provider preferences. Conventional first-line therapy includes corticosteroids\, intravenous immunoglobulin\, and watch-and-wait. Second-line treatments include immunosuppressive therapy and splenectomy. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/role-of-new-therapies-in-the-management-of-itp-and-other-haematological-disorders/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/role-of-new.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20201209T190000
DTEND;TZID=Africa/Nairobi:20201209T210000
DTSTAMP:20260425T065351
CREATED:20210817T112547Z
LAST-MODIFIED:20211024T154010Z
UID:5922-1607540400-1607547600@kesho-kenya.org
SUMMARY:Shifting Paradigms In Triple-Negative Breast Cancer (TNBC) With Cancer Immunotherapy
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr.Njoki Njiraini Sponsor: Roche Presenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi.\nProf. Peter Schmid\, Lead\, Centre for Experimental Cancer Medicine\, Barts Cancer Institute\, St Bartholomew’s Hospital the Queen Mary University of London.\nProf. Nadia Harbeck\, MD LMU Breast Center.\n\nTriple-negative breast cancer (TNBC) is a heterogeneous disease with differential gene expression profiles. The morphological subtypes of TNBC include ER\, PR\, and Her 2 Neu Negative cancers. Hormone receptor-negative patients are usually young (mean age 48.8-34%) and are diagnosed with grade III tumors. The biomarkers are different for African\, African American\, and caucasian women The differences have clinical and biological implications which could be targeted for the development of personalized therapeutics. Testing for immunohistochemistry and participation in clinical trials may improve disease management\, which is a global challenge as well as in Kenya. Poor handling of collected samples\, challenges with sample analysis\, quality control\, and data registry affect data collection in Kenya. There are challenges with the correct pathologic diagnosis\, as a result of differences in diagnostic methods. Testing for immunohistochemistry and participation in clinical trials may improve disease management. Data generated by molecular and genomic profiling is promising to open new therapeutic options. Today\, neoadjuvant therapy is the standard for early TNBC management. Immunotherapies targeting single-agent anti-PD-L1/PD-1 in combination with chemotherapy are effectively treating TNBC\, with good tolerability. Sacituzumab is a new antibody-conjugate in the treatment of TNBC. Other treatment options involve offering multiple lines of treatment\, where standard chemotherapy contains anthracyclines and taxanes. However\, the cost of treatment and diagnostics is still a big challenge in Kenya.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/shifting-paradigms-in-triple-negative-breast-cancer-tnbc-with-cancer-immunotherapy/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/08/8a91fcc1-a426-4a41-b89c-f636ecccd1f4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20201029T190000
DTEND;TZID=Africa/Nairobi:20201029T203000
DTSTAMP:20260425T065351
CREATED:20210817T103556Z
LAST-MODIFIED:20211024T154027Z
UID:5909-1603998000-1604003400@kesho-kenya.org
SUMMARY:Management Of Sickle Cell Disease: A Multidisciplinary Approach
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Gladwell Gatheca Sponsor: Novartis Presenters: \n\nDr. Fredrick Okinyi\, Lecturer\, hematologist\, University of Nairobi\, Kenya\nDr. Esther Nafula\, Palliative Care Specialist and Head of Department\, KNH Palliative Care Unit\n\nSickle cell disease (SCD) is a neglected genetic disease in sub-Saharan Africa that is responsible for 5-16% of mortality in children under 5 years. Approximately 75% of children die before 5 years of age. SCD has a mortality rate of 58/1000 cases per year. The goals of clinical assessment in to give an impression and confirm the diagnosis in new patients\, to determine the symptomatology\, acute or chronic complications\, stable or unstable in known cases\, to classify the type of crisis and precipitating factors in acutely sick patients\, to decide on the level of care as outpatient/inpatient or referral. Diagnosis for new patients is based on clinical presentation\, family history\, clinical features (signs and symptoms)\, and laboratory testing which can be considered as neonatal screening. Preliminary laboratory tests include full blood counts\, reticulocyte counts\, blood film morphology. Sickling tests can be easily performed in the laboratory of lower-level facilities. Since the test is positive for individuals with sickle cell disease as well as in sickle cell trait\, a Hb separation technique is necessary for a positive test. Confirmatory tests include hemoglobin electrophoresis (HE)\, High-performance Liquid Chromatography (HPLC)\, and Isoelectric Focusing (IEF). The point of care rapid tests has high specificity and sensitivity when compared with the HPLC. They are useful in lower-level facilities. Although rapid tests can identify the hemoglobins Hb A\, Hb S\, and Hb C\, they cannot quantify the different hemoglobins or accurately identify some of the other forms of SCD such as Hb S beta-thalassemia. SCD patients should attend clinics as an outpatient management practice. Acute complications should be managed. Fluid management is an important aspect since SCD patients are at risk of dehydration due to impaired renal concentrating power and poor fluid intake. Simple transfusion may use packed red blood cells\, where the donor hematocrit should be about 0.6. Exchange transfusion may be undertaken to rapidly reduce the percentage of sickle cells in circulation\, especially in severe sickle chest syndrome. The complications of the sickle cell disease range from mild to severe and vary among individuals. Counseling is very important in pre-marital\, early childhood\, Adolescence/ adulthood\, and end of life. Pain management involves the use of strong opioids for severe pain\, weak opioids for moderate pain\, and regular paracetamols.  SCD is incurable often leading to premature death. The patients should be helped to achieve a good death\, mainly through control of pain and other physical symptoms\, accepting death is inevitable\, forgiving others\, reconciling with self\, family\, and God\, and being in control of the dying process.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-sickle-cell-disease-a-multidisciplinary-approach/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163728.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20201027T190000
DTEND;TZID=Africa/Nairobi:20201027T203000
DTSTAMP:20260425T065351
CREATED:20210813T140618Z
LAST-MODIFIED:20211024T153721Z
UID:5894-1603825200-1603830600@kesho-kenya.org
SUMMARY:Breast Cancer Management: A Comprehensive Approach Part 3
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Sponsor: AstraZeneca Presenters: \n\nDr. Daniel Ojuka\, Consultant General & Breast Surgeon & Lecturer\, University of Nairobi\nDr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi\n\nBreast cancer is the most common cancer in women globally. Although the surgery was previously the most successful form of treatment; it was associated with mortality (approximately 15%) and increased morbidity\, hence was abandoned in the 1960s. Consequently\, advances in general anesthesia and antiseptic techniques facilitated more extensive procedures. In Kenya\, the current changes in breast cancer management are driven by early detection and diagnosis and timely referrals\, resulting in better outcomes. Unfortunately\, late diagnosis is still frequent.  The current breast cancer management approach is multidisciplinary\, consisting of a multidisciplinary team (MDT)\, of highly qualified specialists and a coordinator. The MDTs are economical and result in service improvement and better outcomes. To date\, breast surgery involves MRM-Auchoncloss\, skin\, and nipple-sparing mastectomy techniques\, which are selected depending on patient morphology\, breast ptosis\, and type of reconstruction planned.  Since the female breast is a symbol of beauty\, fertility\, and femininity\, and surgery causes disfigurement\, mastectomy for younger women requires proper communication and engagement with the patient\, especially on the use of an aesthetic approach to breast conservation and rehabilitation therapy. Alternative approaches to surgery include hormonal therapy\, targeted therapy\, and chemotherapy\, where the choice depends on the stage\, setting\, disease biology\, patient characteristics\, and the genomic patterns of the patients. A combination of approaches such as the use of neoadjuvant chemotherapy before surgery has proven to be beneficial especially in ulcerated patients. Considering the anatomical and molecular staging\, the stage-based treatment survival rate is dependent on the subtypes of breast cancer. The national cancer treatment protocols and training programs for capacity building have been availed to all the counties by the Ministry of Health\, Kenya\, to support the treatment of cancer patients\, especially in the counties.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/breast-cancer-management-a-comprehensive-approach/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163708.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20201021T190000
DTEND;TZID=Africa/Nairobi:20201021T203000
DTSTAMP:20260425T065351
CREATED:20210813T135003Z
LAST-MODIFIED:20211024T154040Z
UID:5888-1603306800-1603312200@kesho-kenya.org
SUMMARY:Breast Cancer Early Diagnosis and Screening Part 2
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Vera Manduku Presenters: \n\nDr. Mary Nyangasi\, Head of Division\, National Cancer Control Program\, Ministry of Health\, Kenya\nDr. Miriam Mutebi\, Consultant\, Breast Surgical Oncologist\, Aga Khan University Hospital\n\nThe ministry of health is commemorating the annual national breast cancer awareness month 2020 by giving hope and saving the lives of breast cancer patients. Globally\, cancer is a major cause of death\, accounting for 1 out of 6 deaths annually. Over 70% of deaths occur in low and middle-income countries\, where breast cancer accounts for 6.6% of all cancer deaths. In Kenya\, cancer is the second leading cause of death from non-communicable diseases\, accounting for 7% of overall mortality. Breast cancer is the third leading cause of death after esophageal and cervical cancers. Good prognosis is associated with timely screening and early detection\, followed by timely treatment. Unfortunately\, awareness and uptake of screening services remain low in Kenya. Consequently\, 70% of breast cancer cases are diagnosed in advanced stages. Since survival of breast cancer patients is highly dependent on the stage of diagnosis\, a low survival rate is observed in stage IV patients. To support the management of breast cancer\, the ministry of health\, Kenya has put infrastructure for screening mammography in all the 47 County Referral Hospitals. In addition\, the ministry has provided national cancer screening guidelines (2018) to guide an organized and unified approach for screening priority cancers including cervix\, breast\, colorectal\, prostate\, and retinoblastoma.  Mammography is the recommended method of screening for women in the average-risk population\, and the only screening modality shown to reduce breast cancer mortality. Previous studies have shown that screening mammography helps with the early detection of cancer and greatly reduces breast cancer deaths for women aged 40-74 years as well as those above 74 years. However\, mammography is very costly and is only recommended for countries with good health infrastructure that can afford long-term programs. Other early detection techniques include a clinical breast examination\, ultrasound\, monthly breast self-examination\, and breast self-awareness. Breast cancer management in low and middle-income countries is complicated by poor health systems\, poverty\, and retrogressive cultural practices. In these countries\, awareness of early signs and symptoms and screening by clinical breast examinations are recommended for the early detection of breast cancer. In Kenya\, screening is mainly opportunistic\, mainly due to challenges associated with lack of equipment\, radiologists\, and radiology personnel. The risk of breast cancer is stratified into two: the average-risk population\, accounting for 80%\, while the high-risk population (20%). While there is a need for risk reduction strategies\, the risks involved in mammography are non-lethal; hence screening benefits outweigh the risks involved. Some of the risks include recall for additional imaging\, needle biopsy\, false positives\, anxiety\, and over-diagnosis. Lifestyle and environmental factors can have an impact on breast cancer risk. Some of the risk reduction measures include maintaining a healthy weight\, exercising regularly\, and limiting the amount of alcohol.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/breast-cancer-early-diagnosis-and-screening/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163658.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20201013T190000
DTEND;TZID=Africa/Nairobi:20201013T203000
DTSTAMP:20260425T065351
CREATED:20210813T134000Z
LAST-MODIFIED:20211024T154048Z
UID:5883-1602615600-1602621000@kesho-kenya.org
SUMMARY:Childhood Cancers and Early Detection
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Sitna Mwanzi \nPresenters: \n\nDr. Valerian Mwenda\, Medical epidemiologist\, Lead Cancer registration\, Monitoring\, Evaluation and Research\, Division of National Cancer Control Program\, Ministry of Health.\nDr. Doreen Karimi Mutua\, Paediatric\, hematologist/ oncologist\, Gertrude’s Children’s Hospital\, Childhood Cancer Initiative\n\nChildhood cancer is becoming a public health crisis in the developing world. In high-income countries\, the childhood cancer prevalence is only 20%\, with up to 80% cure rates. Low and middle-income countries account for 80% of all new cancer cases and less than 20% survival rates. In 2018\, 3000 new cases of childhood cancers were reported in Kenya\, where the survival rate is less than 19-30%. The low survival rate is attributed to the late presentation of patients\, lack of knowledge and awareness of symptoms and signs among health care workers\, weak referral systems\, few cancer diagnostic and treatment centers\, cultural beliefs and myths\, and financial constraints. To overcome these challenges\, there is a need to raise awareness among caregivers and health care workers on early warning signs\, encourage health-seeking behavior among Kenyans\, strengthen referral systems to avoid time wastage\, equip and train staff to diagnose and treat\, adopt evidence-based protocols for the treatment of cancer patients\, maintain data on the outcomes\, and use it for treatment and resource planning. The global initiative for childhood cancer target for 2030 is to realize a double cure rate\, ensuring at least 60% survival for children with cancer globally\, and reducing suffering for all. To achieve this\, efforts are being put in place to increase the capacity of countries to provide quality services for children with cancer\, and to increase the prioritization of childhood cancer at the global\, regional\, and national levels. According to Kenya National Cancer Registry\, the most common childhood cancers are Leukemia\, Retinoblastoma\, Renal\, Lymphoma\, and Central Nervous System. The risk factors are majorly unknown\, though exposure to ionizing radiation and infectious agents has been associated with some cancers. The goal of the Kenya Cancer Policy is to provide a multi-sectoral framework to comprehensively address the cancer burden in the country. The national cancer control strategy (2017-2022) aims to optimize treatment and palliative care for childhood cancers. The national cancer screening guidelines guide early diagnosis while the national cancer treatment protocols guide treatment.  Barriers to effective childhood cancer control include a low level of awareness\, low index of suspicion among the caregivers\, poor referral systems\, and inadequate access to palliative care. Other system challenges include poor access to health care\, lack of finances\, and inadequate surveillance and tracking systems.  To counter these challenges the ministry of health Kenya is increasing advocacy\, training among the health care providers\, and universal health coverage.  Early detection of childhood cancer is key to improved survivorship and health outcomes\, timely access to treatment and care\, lower intensity of treatment\, cost-saving for families and health systems\, and a lower burden of short and long-term toxicity. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n  \n  \n  \n  \n\n\n  \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/childhood-cancers-and-early-detection/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163619.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20201008T191500
DTEND;TZID=Africa/Nairobi:20201008T203000
DTSTAMP:20260425T065351
CREATED:20210812T095227Z
LAST-MODIFIED:20211024T153727Z
UID:5878-1602184500-1602189000@kesho-kenya.org
SUMMARY:The Role of Immunotherapy in Cancer Management
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Miriam Mutebi \nSponsor: Beacon \nPresenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi.\n\nImmunotherapy is a type of cancer treatment that boosts the body’s natural defenses to fight cancer cells. It uses substances made by the body or in a laboratory to improve how your immune system works to find and destroy cancer cells. Traditional therapies such as surgery\, radiation\, and cytotoxic/targeted therapy target tumor cells\, while immunotherapy harnesses the body’s immune system to fight diseases. Anti-tumor immunotherapy includes cancer vaccines that educate T cells to better recognize and kill the pre-existing tumor. Adoptive immunotherapy activates and increases T cell numbers to better kill tumor cells. Immunomodulation uses drugs or antibodies to either increase stimulation or to overcome immune inhibition. Many tumors escape the immune response by creating an immunosuppressive microenvironment that prevents an effective anti-tumor response\, mainly through the involvement of the immune checkpoints located in the central or peripheral regions. The immune checkpoints PD-L1 binds to PD-1 and inhibits T cell killing of tumor cell\, therefore\, blocking PD-L1 or PD-1 allows T cell killing of tumor cells\, while CTLA4 regulate the early phase of activation of naïve and memory T cells in response to T cell receptor (TCR) stimulation by peptides presented by MHC ligands expressed by antigen-presenting and processing cells. Its upregulation prevents normal T cell activation. Several checkpoint inhibitors with FDA approval are in clinical use and have proven to be highly effective in the treatment of relapsed\, progressive solid cancers\, with relatively mild but distinct safety profiles. Some immune checkpoint inhibitors available in Kenya\, are quite costly\, and hence National Hospital Insurance Fund (NHIF) is too little to cover for this treatment. Aga Khan is building capacity for PD-L1 analysis\, an immunohistochemistry test\, in addition to next-generation sequencing. More data is required on the safety of immunotherapy and its use on immunocompromised individuals e.g. HIV\, and those with autoimmune diseases\, Since several clinical trials\, are in progress; more new indications are likely to emerge.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/the-role-of-immunotherapy-in-cancer-management/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210812_124901.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200929T190000
DTEND;TZID=Africa/Nairobi:20200929T203000
DTSTAMP:20260425T065351
CREATED:20210604T163946Z
LAST-MODIFIED:20211024T154727Z
UID:5302-1601406000-1601411400@kesho-kenya.org
SUMMARY:Management of Hormone Receptor Positive Breast Cancer
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-hormone-receptor-positive-breast-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193725.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200915T191500
DTEND;TZID=Africa/Nairobi:20200915T203000
DTSTAMP:20260425T065351
CREATED:20210817T111009Z
LAST-MODIFIED:20211024T154755Z
UID:5918-1600197300-1600201800@kesho-kenya.org
SUMMARY:Management of Neuroendocrine Tumors
DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Moderator: Dr. Sitna Mwanzi \nSponsor: Novartis \nPresenters: \n\nNjoki Njiraini\, a consultant clinical oncologist based at the Cancer Centre in Kenyatta University Teaching Research and Referral Hospital.\n\nNeuroendocrine Neoplasms arise from diffuse neuroendocrine cells in the body and are broadly divided into well-differentiated neuroendocrine tumors (NETs)\, including the sporadic small intestine\, pancreatic\, thorax\, and thymus NETs\, and poorly differentiated neuroendocrine carcinomas (NECs)\, classified based on differentiation\, Ki67 levels\, and mitotic figures. NETs arise from neuroendocrine cells throughout the body. There has been increasing incidence over the last 15 years\, with a male preponderance and a more adverse outcome. Diagnosis is mainly through histology and immunohistochemistry. Staging for NECs is mainly by adenocarcinoma staging system\, which mainly involves imaging through CT scan\, MRI\, Contrast-Enhanced USS\, endoscopic USS\, and functional imaging. Treatment is dependent on TNM staging and grading of the disease and includes surgery\, somatostatin analogs\, hepatic-directed therapies\, and chemotherapeutics. For a patient with carcinoid syndrome\, the short-acting octreotide can be considered first\, while waiting for long-acting octreotide to act. Locally\, therapies are available in 20 mg from Novartis retailing at 68000 Kenya shillings\, but 30mg are also available in the market through other distributors. The toxicity profiles should be put into consideration e.g. diarrhea\, although sometimes it’s difficult to differentiate drugs’ side effects from the initial tumor signs. Neuroendocrine carcinomas are classified as small or large cells and mostly the patients have poor outcomes. There is a need to improve imaging and multidisciplinary teams to share local experiences of neuroendocrine patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n\n\n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-neuroendocrine-tumors-2/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_171140.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200908T191500
DTEND;TZID=Africa/Nairobi:20200908T203000
DTSTAMP:20260425T065351
CREATED:20210817T105953Z
LAST-MODIFIED:20211024T154816Z
UID:5914-1599592500-1599597000@kesho-kenya.org
SUMMARY:Management of Iron Overload
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Paresh Dave \nSponsor: Novartis \nPresenters: \n\nPeter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nIron overload is a poly etiologic condition characterized by a moderate to severe increase in the body iron that has or will have negative effects secondary to iron deposition in tissues or body organs. It may be hereditary or acquired. It is important to detect the disease before organ damage occurs. Iron overload affects overall survival partly due to the underlying biology of the disease but also because of the sequelae of iron overload\, including cardiomyopathy\, cardiac events\, liver disease\, and the development of diabetes. For patients with higher serum ferritin levels\, the 100-day post-transplant mortality is worse with inferior overall survival (OS) and a higher rate of graft vs host disease.  Therefore\, iron chelation therapy can improve OS and is effective at reducing serum ferritin levels\, cardiac events\, and diabetes in patients with blood-transfusion-related iron overload. Compliance is highly encouraged to realize successful treatment. The safety profile of each chelator should be evaluated before the initiation of treatment. Patients receiving chemotherapy and who have a drop in blood count parameters require evaluation to find out the causes. Iron studies are required to generate more data. Iron supplementary can be toxic. Patients with severe organ dysfunction can have a combination of iron chelation therapy.  Ferritin levels should be done every 3 months.  Iron chelation OS is not contraindicated in HIV patients with evidence of iron overload.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-iron-overload/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170945.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200827T070000
DTEND;TZID=Africa/Nairobi:20200827T203000
DTSTAMP:20260425T065351
CREATED:20210604T162505Z
LAST-MODIFIED:20211024T154948Z
UID:5294-1598511600-1598560200@kesho-kenya.org
SUMMARY:Cancer and Thrombosis Current Perspective
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Webinar Recording                 \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-and-thrombosis-current-perspective/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193129.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200811T191500
DTEND;TZID=Africa/Nairobi:20200811T201500
DTSTAMP:20260425T065351
CREATED:20210813T143324Z
LAST-MODIFIED:20250622T142511Z
UID:5898-1597173300-1597176900@kesho-kenya.org
SUMMARY:Emerging Therapies in Hodgkin's Lymphoma Management - Treatment Beyond The Basics
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Miriam Mutebi \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nDr. Anna Sureda\, Head of the Clinical Hematology Department and the Stem Cell Transplantation program of Institut Catala d’Oncologia – Hospitalet\, Barcelona\n\nHodgkin’s lymphoma (HL) is one of the most curable hematological malignancies with first-line treatment\, which is a combination of radiotherapy and chemotherapy. Autologous hematopoietic stem cell transplantation (auto-HCT) is the standard therapy for HL patients relapsing after first-line chemotherapy. The use of allogeneic stem cell transplantation (ASCT) has improved the overall survival (OS) of patients over time.  To improve the landscape of chemotherapy treatment for refractory disease\, a new drug\, Brentuximab vedotin\, has been introduced. This drug is an antibody-drug conjugate (ADC) consisting of 3 components; it binds to CD30 forming a complex that is internalized and traffics to the lysosome. The drug was granted accelerated approval by the US FDA in 2011.  The European Medicines Agency (EMA) approved this drug in 2012 for the treatment of adult patients with relapsed or refractory CD30+ HL\, anaplastic large cell lymphoma\, and those at increased risk of relapse or progression following ASCT. The efficacy reported as median observation time from the first dose at study closure was 35.1 months (1.8-72.9). Studies revealed that Brentuximab vedotin and ESHAP are highly effective as second-line therapy for Hodgkin’s patients. Brentuximab vedotin was the first targeted therapy that was tested in patients with relapsed/refractory HL. It was very effective as a single drug in patients that relapse or progress after auto-HCT. Brentuximab vedotin is able to potentially increase the number of patients that are candidates to auto-HCT. It improves progression-free survival (PFS) in those patients with a high risk of relapse after auto-HCT when used as a consolidation strategy. It has demonstrated an adequate and safe toxicity profile\, even in HIV-positive patients with HL. Brentuximab vedotin is being used in other settings with very interesting results (RR setting in combination with chemotherapy\, first line). However\, the cost of the treatment in Kenya is quite high; a single vial costs Kshs. 330\,000. A patient assistance program in partnership with Takeda is helping patients in Kenya who cannot afford to pay\, to complete their treatment. Although this program is run in private hospitals\, physicians seeing patients at public facilities can refer the patients to the private facilities for assistance\, but continue to follow up on the patients. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/emerging-therapies-in-hodgkins-lymphoma-management-treatment-beyond-the-basics/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170809.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200730T191500
DTEND;TZID=Africa/Nairobi:20200730T203000
DTSTAMP:20260425T065351
CREATED:20210810T101728Z
LAST-MODIFIED:20250622T142511Z
UID:5839-1596136500-1596141000@kesho-kenya.org
SUMMARY:Ovarian Cancer\, The Good\, The Bad\, And The Ugly
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi \nSponsor: Merck \nPresenters: \n\nDr. Benjamin Odongo Elly\, Gynecologic Oncologist at Moi Teaching and Referral University.\n\nMoi Teaching and Referral Hospital (MTRH) cancer center offers a holistic approach to cancer treatment. Germ cell tumors account for 10-115% of all ovarian tumors and affect young females of reproductive age. They are very chemosensitive hence are curable\, using fertility-sparing surgery. Stromal tumors account for 3-5% of all ovarian tumors and affect women of all ages. These tumors are diagnosed early and are histologically low-grade\, with a good prognosis\, when treated with surgery\,  followed by adjuvant treatment. However\, some tumors are aggressive and lethal. Epithelial tumors represent 80-85% of all ovarian tumors. They have a poor prognosis and are always detected late. Warning signs include abdominal bloating\, abdominal/pelvic pain\, bowel/bladder symptoms\, and irregular vaginal bleeding. Prevention of ovarian cancer is by avoidance of risk factors and prophylactic surgery in high-risk women. There is currently no good screening test for the general population. Diagnosis is by appropriate physical examination\, pelvic/transvaginal ultrasound\, tumor markers\, and CT scan. The majority of patients are diagnosed with advanced-stage disease (stage III or IV) leading to poor overall 5-year survival. However\, patients are living longer with the disease due to advances in surgery and chemotherapy treatment. As a country\, there is a need to improve the early diagnosis of ovarian cancer through advocacy\, patient education\, human resource\, training capacity building\, and availing resources to the health care facilities.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ovarian-cancer-the-good-the-bad-and-the-ugly/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
END:VEVENT
END:VCALENDAR